216 related articles for article (PubMed ID: 33938570)
21. Severe hemolytic disease of the fetus and newborn due to allo-anti-D in a patient with a partial DEL phenotype arising from the variant allele described as RHD*148+1T (RHD*01EL.31).
Turley E; McGowan EC; Hyland CA; Schoeman EM; Flower RL; Skoll A; Delisle MF; Nelson T; Clarke G; Au N
Transfusion; 2018 Oct; 58(10):2260-2264. PubMed ID: 30222865
[TBL] [Abstract][Full Text] [Related]
22. Successful management of severe Kell alloimmunization in pregnancy with intravenous immune globulin.
Patris M; Holoye A; Goldman D; De Coninck C; Colard M
Transfus Apher Sci; 2024 Apr; 63(2):103868. PubMed ID: 38238203
[TBL] [Abstract][Full Text] [Related]
23. Fetal and Neonatal Reticulocyte Count Response to Intrauterine Transfusion for the Treatment of Red Blood Cell Alloimmunization.
Lee AJ; Leonard A; Markham KB
J Pediatr Hematol Oncol; 2022 Nov; 44(8):e1046-e1049. PubMed ID: 35380549
[TBL] [Abstract][Full Text] [Related]
24. The role of the fetal immune system in the pathogenesis of RhD-hemolytic disease of newborns.
Gurevich P; Erina S; Gershon S; Zusman I
Hum Antibodies; 1997; 8(2):76-89. PubMed ID: 9289392
[TBL] [Abstract][Full Text] [Related]
25. Management and clinical consequences of red blood cell antibodies in pregnancy: A population-based cohort study.
Liu S; Ajne G; Wikman A; Lindqvist C; Reilly M; Tiblad E
Acta Obstet Gynecol Scand; 2021 Dec; 100(12):2216-2225. PubMed ID: 34476807
[TBL] [Abstract][Full Text] [Related]
26. Fetal and neonatal outcome in severe alloimmunization managed with intrauterine transfusion: 18-year experience in a tertiary referral hospital in China.
Pan W; Wu H; Chen J; Mo X; Wang H; Fang Q; Li Y; Huang Y
Front Pediatr; 2023; 11():1157004. PubMed ID: 37124190
[TBL] [Abstract][Full Text] [Related]
27. Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment.
Weiner CP; Williamson RA; Wenstrom KD; Sipes SL; Widness JA; Grant SS; Estle L
Am J Obstet Gynecol; 1991 Nov; 165(5 Pt 1):1302-7. PubMed ID: 1957851
[TBL] [Abstract][Full Text] [Related]
28. Management of pregnancies complicated by anti-E alloimmunization.
Joy SD; Rossi KQ; Krugh D; O'Shaughnessy RW
Obstet Gynecol; 2005 Jan; 105(1):24-8. PubMed ID: 15625137
[TBL] [Abstract][Full Text] [Related]
29. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape.
de Winter DP; Kaminski A; Tjoa ML; Oepkes D
BMC Pregnancy Childbirth; 2023 Jan; 23(1):12. PubMed ID: 36611144
[TBL] [Abstract][Full Text] [Related]
30. Management of fetal hemolytic disease by cordocentesis. I. Prediction of fetal anemia.
Weiner CP; Williamson RA; Wenstrom KD; Sipes SL; Grant SS; Widness JA
Am J Obstet Gynecol; 1991 Sep; 165(3):546-53. PubMed ID: 1892178
[TBL] [Abstract][Full Text] [Related]
31. A single-center, retrospective analysis of 17 cases of hemolytic disease of the fetus and newborn caused by anti-M antibodies.
He Y; Gao W; Li Y; Xu C; Wang Q
Transfusion; 2023 Mar; 63(3):494-506. PubMed ID: 36727659
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation.
Hyland CA; O'Brien H; Flower RL; Gardener GJ
Transfus Apher Sci; 2020 Oct; 59(5):102947. PubMed ID: 33115620
[TBL] [Abstract][Full Text] [Related]
33. Frequency and clinical significance of red cell antibodies in pregnancy - A prospective study from India.
Das S; Shastry S; Rai L; Baliga PB
Indian J Pathol Microbiol; 2020; 63(2):241-246. PubMed ID: 32317523
[TBL] [Abstract][Full Text] [Related]
34. Anti-D in a mother, hemizygous for the variant RHD*DNB gene, associated with hemolytic disease of the fetus and newborn.
Quantock KM; Lopez GH; Hyland CA; Liew YW; Flower RL; Niemann FJ; Joyce A
Transfusion; 2017 Aug; 57(8):1938-1943. PubMed ID: 28639307
[TBL] [Abstract][Full Text] [Related]
35. Treatment of D alloimmunization in pregnancy with plasmapheresis and intravenous immune globulin: case report.
Fernández Alba JJ; León R; González-Macías C; Paz A; Prado F; Moreno LJ; Torrejón R
Transfus Apher Sci; 2014 Aug; 51(1):70-2. PubMed ID: 25312036
[TBL] [Abstract][Full Text] [Related]
36. HDFN Resulting from Anti-U: Alternatives to Allogeneic Intrauterine Transfusion.
Caudill JL; Gillard L
Lab Med; 2022 Jul; 53(4):e79-e82. PubMed ID: 34791347
[TBL] [Abstract][Full Text] [Related]
37. Late hyporegenerative anemia in neonates with rhesus hemolytic disease.
al-Alaiyan S; al Omran A
J Perinat Med; 1999; 27(2):112-5. PubMed ID: 10379500
[TBL] [Abstract][Full Text] [Related]
38. Successful use of maternal blood in the management of severe hemolytic disease of the fetus and newborn due to anti-Kp(b).
Bleile MJ; Rijhsinghani A; Dwyre DM; Raife TJ
Transfus Apher Sci; 2010 Dec; 43(3):281-283. PubMed ID: 20951648
[TBL] [Abstract][Full Text] [Related]
39. Management and outcome of pregnancies in women with red cell isoimmunization: a 15-year observational study from a tertiary care university hospital.
Sánchez-Durán MÁ; Higueras MT; Halajdian-Madrid C; Avilés García M; Bernabeu-García A; Maiz N; Nogués N; Carreras E
BMC Pregnancy Childbirth; 2019 Oct; 19(1):356. PubMed ID: 31615430
[TBL] [Abstract][Full Text] [Related]
40. Prolonged anemia in an intrauterine-transfused neonate with Rh-hemolytic disease: no evidence for anti-D-related suppression of erythropoiesis in vitro.
Dorn I; Schlenke P; Härtel C
Transfusion; 2010 May; 50(5):1064-70. PubMed ID: 20003047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
